Blood-Based Lipid Biomarker Panel for Risk-Based Breast Cancer Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current screening methods for breast cancer lack personalized tools for early detection, leading to inconsistencies in screening guidelines and overscreening, with mammography facing scrutiny due to overdiagnosis and lack of individualized risk assessment tools.
Innovation Solution
A lipid-based biomarker panel comprising ceramides, sphingomyelins, glycosphingolipids, and free fatty acids is used to identify individuals at increased risk of breast cancer, enabling personalized risk assessment and tailored screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If screening mammography is performed for all women in standard age groups, then breast cancer detection coverage is improved, but overdiagnosis and overscreening occur
Solution Approach 1:
The patent segments the population into different risk groups based on lipid biomarker profiles (high-risk, intermediate-risk, low-risk), allowing tailored screening strategies for each segment rather than uniform screening for all women, thereby reducing overdiagnosis while maintaining detection coverage
Solution Approach 2:
The patent uses lipid biomarker parameters (ceramides, sphingomyelins, glycosphingolipids, free fatty acids) to change the screening approach from age-based to risk-based, enabling personalized screening intervals and methods that reduce harmful overdiagnosis while improving detection efficiency
2Productivity
If personalized risk assessment tools are developed, then screening efficiency is improved, but current lack of such tools causes inconsistencies in screening guidelines
Solution Approach 1:
The patent introduces lipid biomarker panels as intermediary tools that mediate between standard mammography screening and individualized risk assessment, providing the missing personalized information that currently causes guideline inconsistencies and enabling more efficient screening decisions
3Measurement precision
If metabolic syndrome biomarkers are measured, then identification of high-risk individuals is improved, but current screening methods lack this personalized approach
Solution Approach 1:
The patent makes the lipid biomarker panel a universal tool that can be integrated into existing clinical workflows and used across different patient populations, providing precise risk identification without requiring entirely new complex screening systems, thus improving accuracy while managing complexity
Data Source
AI summary
A novel 11-lipid biomarker panel, consisting of or comprising at least one ceramide, at least one sphingomyelin, at least one glycosphingolipid, and at least one free fatty acid, capable of assessing the risk of breast cancer is described.